Premium
Suppression of urokinase‐type plasminogen activator mRNA levels in human fibrosarcoma cells and synovial fibroblasts by anti‐inflammatory glucocorticoids.
Author(s) -
Medcalf R.L.,
Richards R.I.,
Crawford R.J.,
Hamilton J.A.
Publication year - 1986
Publication title -
the embo journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.484
H-Index - 392
eISSN - 1460-2075
pISSN - 0261-4189
DOI - 10.1002/j.1460-2075.1986.tb04487.x
Subject(s) - biology , plasminogen activator , fibrosarcoma , messenger rna , microbiology and biotechnology , urokinase , endocrinology , medicine , cancer research , gene , biochemistry , genetics
Suppression of plasminogen activator (PA) activity has been invoked as being part of the general anti‐inflammatory action of glucocorticoids. Low concentrations of the synthetic glucocorticoid, dexamethasone (Dex), reduce urokinase‐type PA mRNA levels in two cell types, namely a human fibrosarcoma line, HT1080, and synovial fibroblast‐like cells isolated from human joints. Conversely, metallothionein IIa (MTIIa) mRNA levels in these cells are raised by Dex. These findings, by suggesting that it is possible to suppress urokinase‐type PA activity at the level of gene expression, may have therapeutic implications for diseases such as rheumatoid arthritis where proteases may be contributing to the extensive tissue damage and inflammation.